CY1106095T1 - Παραγωγα πιπεριδινης χρησιμα ως ρυθμιστες δρασης υποδοχεα χημειοκινων - Google Patents
Παραγωγα πιπεριδινης χρησιμα ως ρυθμιστες δρασης υποδοχεα χημειοκινωνInfo
- Publication number
- CY1106095T1 CY1106095T1 CY20061100755T CY061100755T CY1106095T1 CY 1106095 T1 CY1106095 T1 CY 1106095T1 CY 20061100755 T CY20061100755 T CY 20061100755T CY 061100755 T CY061100755 T CY 061100755T CY 1106095 T1 CY1106095 T1 CY 1106095T1
- Authority
- CY
- Cyprus
- Prior art keywords
- optionally substituted
- chemokine receptor
- receptor modulators
- derivatives useful
- piperidine derivatives
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title 1
- 108050000299 Chemokine receptor Proteins 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Η εφεύρεση παρέχει μία ένωση του τύπου (I), όπου: το Τ είναι C(O) ή S(O)2· το W είναι C(O) ή S(O)2· το Χ είναι CH2, Ο ή ΝΗ· το Υ είναι CR5 ή Ν· το R1 είναι προαιρετικά υποκατεστημένο αρυλ ή προαιρετικά υποκατεστημένο ετεροκυκλυλ· το R2 είναι υδρογόνο ή C1-6αλκυλ· το R3 είναι υδρογόνο ή προαιρετικά υποκατεστημένο C1-6αλκυλ· και το R4 είναι αλκυλ, προαιρετικά υποκατεστημένο αρυλ, προαιρετικά υποκατεστημένο αραλκυλ ή προαιρετικά υποκατεστημένο ετεροκυκλυλ· που είναι ρυθμιστές της δράσης χημειοκινών (ειδικότερα της CCR3) και είναι ιδιαίτερα χρήσιμα στη θεραπευτική αντιμετώπιση του άσθματος και/ή της ρινίτιδας.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0116179A GB0116179D0 (en) | 2001-07-02 | 2001-07-02 | Chemical compounds |
| GB0123037A GB0123037D0 (en) | 2001-09-25 | 2001-09-25 | Chemical compounds |
| PCT/SE2002/001311 WO2003004487A1 (en) | 2001-07-02 | 2002-07-01 | Piperidine derivatives useful as modulators of chemokine receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106095T1 true CY1106095T1 (el) | 2011-06-08 |
Family
ID=26246268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100755T CY1106095T1 (el) | 2001-07-02 | 2006-06-07 | Παραγωγα πιπεριδινης χρησιμα ως ρυθμιστες δρασης υποδοχεα χημειοκινων |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7307090B2 (el) |
| EP (2) | EP1404667B1 (el) |
| JP (1) | JP3857270B2 (el) |
| KR (1) | KR20040013090A (el) |
| CN (1) | CN1545509A (el) |
| AR (1) | AR042401A1 (el) |
| AT (1) | ATE319703T1 (el) |
| BR (1) | BR0210733A (el) |
| CA (1) | CA2452597A1 (el) |
| CO (1) | CO5540307A2 (el) |
| CY (1) | CY1106095T1 (el) |
| DE (1) | DE60209736T2 (el) |
| DK (1) | DK1404667T3 (el) |
| ES (1) | ES2258642T3 (el) |
| HK (1) | HK1062559A1 (el) |
| HU (1) | HUP0401886A2 (el) |
| IL (1) | IL159256A0 (el) |
| IS (1) | IS7094A (el) |
| MX (1) | MXPA03011722A (el) |
| NO (1) | NO20035729L (el) |
| NZ (1) | NZ530202A (el) |
| PL (1) | PL368041A1 (el) |
| PT (1) | PT1404667E (el) |
| RU (1) | RU2004100839A (el) |
| SA (1) | SA02230184B1 (el) |
| WO (1) | WO2003004487A1 (el) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| WO2003059965A1 (en) * | 2002-01-10 | 2003-07-24 | University Of Washington | Hydrogels formed by non-covalent linkages |
| AU2003209388A1 (en) * | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| SE0200843D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| CA2479362C (en) * | 2002-03-21 | 2011-01-04 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| US7030115B2 (en) * | 2002-03-21 | 2006-04-18 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| PE20040167A1 (es) | 2002-03-28 | 2004-05-26 | Novartis Ag | Amidas del acido sulfamico |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| US20040192738A1 (en) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
| SE0403003D0 (sv) * | 2004-12-09 | 2004-12-09 | Astrazeneca Ab | Chemical compound 1 |
| WO2006071875A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| EP1888527A1 (en) * | 2005-05-27 | 2008-02-20 | AstraZeneca AB | Piperidines for the treatment of chemokine mediated diseases |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| KR20080037655A (ko) | 2005-07-21 | 2008-04-30 | 아스트라제네카 아베 | 신규 피페리딘 유도체 |
| EP1957076A2 (en) * | 2005-11-29 | 2008-08-20 | Merck & Co., Inc. | Thiazole derivatives as cxcr3 receptor modulators |
| CN101378756A (zh) * | 2006-02-10 | 2009-03-04 | 詹森药业有限公司 | 作为cxcr3受体拮抗剂的哌啶衍生物 |
| JP2009526014A (ja) * | 2006-02-10 | 2009-07-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃｘｃｒ３受容体拮抗薬としてのピペリジン誘導体 |
| WO2009038974A1 (en) | 2007-09-20 | 2009-03-26 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| CN105001196B (zh) | 2008-12-03 | 2017-05-10 | 斯克里普斯研究所 | 干细胞培养 |
| CA3075638A1 (en) | 2017-09-25 | 2019-03-28 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| TWI730297B (zh) * | 2018-02-27 | 2021-06-11 | 日商組合化學工業股份有限公司 | 巰基酚化合物的製造方法及巰基酚化合物的中間體 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1250719A (el) | 1969-03-19 | 1971-10-20 | ||
| US4556660A (en) | 1982-07-12 | 1985-12-03 | Janssen Pharmaceutica N.V. | N-(Bicyclic heterocyclyl)-4-piperidinamines |
| DK139684A (da) | 1983-04-11 | 1984-10-12 | Janssen Pharmaceutica Nv | N-aryl-alpha-amino-carboxamider |
| US4634704A (en) | 1983-10-06 | 1987-01-06 | Janssen Pharmaceutica, N.V. | Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines |
| PH23995A (en) | 1984-01-09 | 1990-02-09 | Janssen Pharmaceutica Nv | 4((bicycle heterocyclyl)-methyl and hetero)piperidines |
| US4588722A (en) | 1984-01-09 | 1986-05-13 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives |
| US4695575A (en) | 1984-11-13 | 1987-09-22 | Janssen Pharmaceutica, N.V. | 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines |
| AU2915892A (en) | 1991-11-14 | 1993-06-15 | Glaxo Group Limited | Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation |
| GB9319534D0 (en) | 1993-09-22 | 1993-11-10 | Boots Co Plc | Therapeutic agents |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| AU5966096A (en) | 1995-06-09 | 1997-01-09 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| HUP9904622A3 (en) | 1996-07-10 | 2001-07-30 | Schering Corp | 1,4-di-sustituted piperidines as muscarinic antagonists |
| EP0821954A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating mental retardation |
| US5977138A (en) | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
| ATE297381T1 (de) * | 1996-08-15 | 2005-06-15 | Schering Corp | Ether-muskarinantagonisten |
| CA2262818A1 (en) | 1996-09-10 | 1998-03-19 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Modified amino acids, pharmaceuticals containing these compounds and methods for their production |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| UA59433C2 (uk) | 1998-01-27 | 2003-09-15 | Авентіс Фармасьютікалс Продактс Інк. | ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ |
| JP2002501898A (ja) | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
| TWI245763B (en) | 1998-04-02 | 2005-12-21 | Janssen Pharmaceutica Nv | Biocidal benzylbiphenyl derivatives |
| KR20010043032A (ko) | 1998-04-28 | 2001-05-25 | 도모따께 다께시 | 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체 |
| US6066636A (en) | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
| ES2221399T3 (es) | 1998-06-30 | 2004-12-16 | Schering Corporation | Antagonistas muscarinicos. |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| WO2000032590A1 (en) | 1998-11-25 | 2000-06-08 | Aventis Pharmaceuticals Products Inc. | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
| US6331545B1 (en) | 1998-12-18 | 2001-12-18 | Soo S. Ko | Heterocycyclic piperidines as modulators of chemokine receptor activity |
| HUP0203528A3 (en) * | 1999-05-04 | 2003-11-28 | Schering Corp | Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use |
| US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| SE9902551D0 (sv) | 1999-07-02 | 1999-07-02 | Astra Pharma Prod | Novel compounds |
| IL147495A0 (en) | 1999-07-28 | 2002-08-14 | Aventis Pharm Prod Inc | Substituted oxoazaheterocycclyl compounds |
| IT1307809B1 (it) | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono. |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
| GB0021670D0 (en) * | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0107907D0 (en) | 2001-03-29 | 2001-05-23 | Smithkline Beecham Plc | Novel compounds |
| DK1373256T3 (da) | 2001-03-29 | 2005-10-10 | Schering Corp | CCR5-antagonister, der er nyttige til behandling af AIDS |
| GB0108876D0 (en) | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AR036366A1 (es) | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0202838D0 (sv) | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300850D0 (sv) | 2003-03-25 | 2003-03-25 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0301368D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| CA2529161A1 (en) | 2003-06-13 | 2004-12-29 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
-
2002
- 2002-07-01 BR BR0210733-3A patent/BR0210733A/pt not_active IP Right Cessation
- 2002-07-01 MX MXPA03011722A patent/MXPA03011722A/es active IP Right Grant
- 2002-07-01 DE DE60209736T patent/DE60209736T2/de not_active Expired - Lifetime
- 2002-07-01 AT AT02747793T patent/ATE319703T1/de not_active IP Right Cessation
- 2002-07-01 PL PL02368041A patent/PL368041A1/xx not_active Application Discontinuation
- 2002-07-01 JP JP2003510654A patent/JP3857270B2/ja not_active Expired - Fee Related
- 2002-07-01 CN CNA028162714A patent/CN1545509A/zh active Pending
- 2002-07-01 HU HU0401886A patent/HUP0401886A2/hu unknown
- 2002-07-01 RU RU2004100839/04A patent/RU2004100839A/ru not_active Application Discontinuation
- 2002-07-01 NZ NZ530202A patent/NZ530202A/en unknown
- 2002-07-01 PT PT02747793T patent/PT1404667E/pt unknown
- 2002-07-01 EP EP02747793A patent/EP1404667B1/en not_active Expired - Lifetime
- 2002-07-01 KR KR10-2004-7000023A patent/KR20040013090A/ko not_active Application Discontinuation
- 2002-07-01 WO PCT/SE2002/001311 patent/WO2003004487A1/en active IP Right Grant
- 2002-07-01 EP EP05018449A patent/EP1604982A1/en not_active Withdrawn
- 2002-07-01 US US10/480,625 patent/US7307090B2/en not_active Expired - Fee Related
- 2002-07-01 IL IL15925602A patent/IL159256A0/xx unknown
- 2002-07-01 DK DK02747793T patent/DK1404667T3/da active
- 2002-07-01 ES ES02747793T patent/ES2258642T3/es not_active Expired - Lifetime
- 2002-07-01 CA CA002452597A patent/CA2452597A1/en not_active Abandoned
- 2002-07-02 AR ARP020102488A patent/AR042401A1/es not_active Application Discontinuation
- 2002-07-02 SA SA02230184A patent/SA02230184B1/ar unknown
-
2003
- 2003-12-19 NO NO20035729A patent/NO20035729L/no not_active Application Discontinuation
- 2003-12-29 CO CO03112957A patent/CO5540307A2/es not_active Application Discontinuation
- 2003-12-30 IS IS7094A patent/IS7094A/is unknown
-
2004
- 2004-07-22 HK HK04105447A patent/HK1062559A1/xx not_active IP Right Cessation
-
2006
- 2006-06-07 CY CY20061100755T patent/CY1106095T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE319703T1 (de) | 2006-03-15 |
| SA02230184B1 (ar) | 2007-03-25 |
| US7307090B2 (en) | 2007-12-11 |
| EP1404667B1 (en) | 2006-03-08 |
| NZ530202A (en) | 2005-06-24 |
| EP1604982A1 (en) | 2005-12-14 |
| PL368041A1 (en) | 2005-03-21 |
| IS7094A (is) | 2003-12-30 |
| RU2004100839A (ru) | 2005-06-20 |
| ES2258642T3 (es) | 2006-09-01 |
| CN1545509A (zh) | 2004-11-10 |
| HUP0401886A2 (hu) | 2004-12-28 |
| IL159256A0 (en) | 2004-06-01 |
| BR0210733A (pt) | 2004-07-20 |
| PT1404667E (pt) | 2006-07-31 |
| DK1404667T3 (da) | 2006-07-10 |
| EP1404667A1 (en) | 2004-04-07 |
| JP2004536112A (ja) | 2004-12-02 |
| DE60209736D1 (de) | 2006-05-04 |
| AR042401A1 (es) | 2005-06-22 |
| NO20035729L (no) | 2004-02-23 |
| WO2003004487A1 (en) | 2003-01-16 |
| KR20040013090A (ko) | 2004-02-11 |
| JP3857270B2 (ja) | 2006-12-13 |
| MXPA03011722A (es) | 2004-03-19 |
| HK1062559A1 (en) | 2004-11-12 |
| US20040235894A1 (en) | 2004-11-25 |
| DE60209736T2 (de) | 2006-11-02 |
| CA2452597A1 (en) | 2003-01-16 |
| CO5540307A2 (es) | 2005-07-29 |
| NO20035729D0 (no) | 2003-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106095T1 (el) | Παραγωγα πιπεριδινης χρησιμα ως ρυθμιστες δρασης υποδοχεα χημειοκινων | |
| CY1115302T1 (el) | Ενωση οξαζολιου και φαρμακευτικη συνθεση | |
| PE20040465A1 (es) | Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa | |
| CY1105907T1 (el) | Νεα παραγωγα της 1,2,4 - θειαδιαζολης ως ρυθμιστες υποδοχεως μελανοκορτινης | |
| CY1112630T1 (el) | Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog | |
| CY1110399T1 (el) | Ρυθμιστες της τετραϋδροπυρανυλο κυκλοπεντυλο τετραϋδροπυριδοπυριδινης για την ενεργοτητα των υποδοχεων των χημειοκινων | |
| DE60213625D1 (de) | Piperidinderivate und deren verwendung als modulatoren der chemokinaktivität (insbesondere der von ccr3) | |
| CY1115536T1 (el) | Νεες υδροξυ-6-ετεροαρυλφαινανθριδινες και χρηση αυτων ως αναστολεις pde4 | |
| CY1108041T1 (el) | Αναστολεις της rho-κινασης | |
| NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| DE60322877D1 (de) | Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität | |
| NO20061126L (no) | Aminopyroner og deres anvendelse som ATM-inhibitorer | |
| ATE543807T1 (de) | Verstärker von glutamat-rezeptoren | |
| NO20023457L (no) | Nye piperidinforbindelser og legemidler inneholdende de samme | |
| CY1108652T1 (el) | Παραγωγα μορφολινυλ-ουριας για χρηση στη θεραπεια φλεγμονωδων ασθενειων | |
| CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
| ATE490253T1 (de) | Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen | |
| CY1109153T1 (el) | Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης | |
| NO20050870L (no) | Fosfodiesterase 4-inhibitorer, inkludert N-substituerte anilin- og difenylaminanaloger | |
| CO4520230A1 (es) | Derivados de [3-(4-fenilpiperacin-1-il) propilamino, tio y oxilo]-piridina, pirimidina y benceno como antagonistas de alfa 1- adrenoceptores | |
| PE20080068A1 (es) | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora | |
| CY1109300T1 (el) | Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων | |
| HRP20050082A2 (en) | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors | |
| CY1106709T1 (el) | Νεες ενωσεις που εχουν επιλεκτικη δραση αναστολης στην gsk3 | |
| ATE498600T1 (de) | Inden derivate als pharmazeutika |